Sarcopenia and Osteoporosis in the Patients With Hemophilia

Completed

• Conditions: Hemophilia; Hemophilic Arthropathy; Sarcopenia; Osteoporosis, Osteopenia
• Interventions: Diagnostic Test: Dual-energy X-ray absorptiometry (DXA)

• Registration Number: NCT04535180
• Lead Sponsor: Tri-Service General Hospital

Brief Summary

Hemophilia is a bleeding disorder and repeated joint bleeding leads to hemophilic arthropathy. Among patients with hemophilia, vitamin D deficiency and hemophilic arthropathy have been associated with osteoporosis in several clinical studies.There is no data on the prevalence of osteoporosis in hemophilia patients in Taiwan or Asia. To the best of our knowledge, no previous studies have reported the prevalence of sarcopenia and correlation with osteoporosis in hemophilia adult patients. This study will investigate the prevalence and corelation of sarcopenia and low BMD in patients with hemophilia.

patients in Taiwan. The study will estimate the prevalence of sarcopenia and body composition in the hemophilia population and compared baseline demographic and clinical characteristics between the non-sarcopenia and sarcopenia individuals, with particular emphasis on the overlap with osteoporosis and hemophilic arthropathy.

Detailed Description

Not available

Study Timeline

• Study Start: 2019-01-01
• Primary Completion: 2019-12-31
• Study Completion: 2019-12-31
• Status Verified: 2020-08
• Study First Submitted: 2020-08-12
• Study First Submitted QC: 2020-08-29
• Last Update Submitted: 2020-08-29
• Study First Posted: 2020-09-01
• Last Update Posted: 2020-09-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 45

Inclusion Criteria

• Hemophilia patients

Read More

Exclusion Criteria

• History of total hip arthroplasty
• History of instrumentation in lumbar spine

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Hemophilia	Dual-energy X-ray absorptiometry (DXA)	-

Primary Outcome Measures

Name	Time	Method
Sacropenia	up to 4 weeks	Extremity skeletal muscle mass will be calculated using the values measured via the DXA

Trial Locations

Locations (1)

Tri-Service General Hospital; 🇨🇳 Taipei, Taiwan